HUC3-637 for primary open-angle glaucoma and ocular hypertension

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a multicenter, randomized, single-blind, active-controlled phase III trial comparing HUC3-637 and HUC3-637-R in adults with primary open-angle glaucoma or ocular hypertension. Eligible participants are age 19 or older, have a diagnosis of POAG or ocular hypertension, and must provide written informed consent; patients with angle-closure, congenital, or secondary glaucoma are excluded. The trial will monitor efficacy and safety outcomes over the treatment period, with scheduled clinic visits at participating centers (detailed endpoints and visit schedule are not provided in the registry entry). The lead sponsor is Huons Co., Ltd., and the listed site for enrollment is Kangbuk Samsung Hospital in Seoul.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Adults aged 19 years and older
* Participants diagnosed with POAG or OH
* Have fully explained and understood the study and have voluntarily given written informed consent.

Exclusion Criteria:

* Acute or chronic angle-closure glaucoma
* Congenital glaucoma, secondary glaucoma (open-angle glaucoma)

Where it's running

• Kangbuk Samsung Hospital
  Seoul, South Korea Recruiting

Study contacts

• Study coordinator: Rang Lee
• Email: rlee@huons.com
• Phone: 07074926091

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Pregabalin eye drops vs timolol eye drops for open-angle glaucoma or ocular hypertension

  A doctor-led study tests whether pregabalin eye drops (TB0001) work as well as timolol eye drops to lower eye pressure in adults with glaucoma or high eye pressure.

  Recruiting at 3 sites Phase 2 Tavo Biotherapeutics · Glendale, California and 2 other locations · NCT07913074

• REGN22530 for Adults With Primary Open Angle Glaucoma or Ocular Hypertension

  This study tests REGN22530 in adults with POAG or ocular hypertension to see if it can lower eye pressure and what kind of side effects it may have.

  Recruiting Phase 1/2 Regeneron Pharmaceuticals · Deerfield Beach, Florida · NCT07675824

• TFC-003: a new eye drop combo for open-angle glaucoma and ocular hypertension

  This study tests whether TFC-003, alone or in slight revisions, can safely lower eye pressure in adults with open-angle glaucoma or ocular hypertension who aren’t yet at their target pressure.

  Recruiting Phase 3 Kukje Pharma · Seongnam · NCT07662759

• Is a preservative-free Bimatoprost 0.01% as effective and safe as Lumigan in POAG or ocular hypertension?

  This study tests whether a preservative-free Bimatoprost 0.01% (YSBP) works as well as Lumigan 0.01% for people with POAG or ocular hypertension.

  Recruiting Phase 3 YS Life Science Co., Ltd. · Beverly Hills, California and 21 other locations · NCT07661329

• Imaging the effect of Netarsudil on the eye’s drainage system in glaucoma and ocular hypertension

  This study tests whether netarsudil eye drops change the trabecular meshwork’s structure compared with placebo in adults with ocular hypertension or open-angle glaucoma.

  Recruiting Phase 4 Indiana University · Bloomington, Indiana · NCT07588152

• Analyzing eye fluid and tissues to find glaucoma-related markers in people with cataracts.

  This study will test whether protein and elemental patterns in eye fluid and tissues taken during cataract surgery differ between people with primary open-angle glaucoma and those without glaucoma.

  Recruiting at 2 sites Military Institute od Medicine National Research Institute · Warsaw and 1 other locations · NCT07462000

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.